

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Obesity and NAFLD: Mechanisms and Therapeutics (B3)

February 23-27, 2020 • Fairmont Banff Springs • Banff, AB, Canada

Scientific Organizers: Rebecca A. Haeusler, Shingo Kajimura and Alexei Kharitonov

Sponsored by Gilead Sciences, Inc. and Novo Nordisk A/S

Discounted Abstract & Scholarship Deadline: October 23, 2019 / Abstract Deadline: November 21, 2019 / Discounted Registration Deadline: December 19, 2019

SUNDAY, FEBRUARY 23

Arrival and Registration

MONDAY, FEBRUARY 24

Welcome and Keynote Address

Mitchell A. Lazar, Perelman School of Medicine, University of Pennsylvania, USA
Transcriptional Regulation of Hepatic Lipid Metabolism

New Pathways in Hepatic Metabolism

Kun-Liang Guan, University of California, San Diego, USA
The Hippo Pathway in Metabolism and Organ Growth

Hannele Yki-Järvinen, University of Helsinki, Finland
Influences of Genetics and Insulin Sensitivity in NAFLD

Mark A. Herman, Duke University Medical Center, USA
Metabolic Effects of Fructose

Short Talks Chosen from Abstracts

Mitochondrial Function in Energy Balance and Metabolic Disease

Brian N. Finck, Washington University School of Medicine, USA
Targeting Mitochondrial Intermediary Metabolism to Treat NAFLD

Johan Auwerx, École Polytechnique Fédérale de Lausanne, Switzerland
ACMSD Inhibition as a Novel Approach for NAD⁺ Boosting via Its De Novo Biosynthesis

Jun Wu, University of Michigan, USA
nicotinic acetylcholine receptors in energy metabolism

Short Talks Chosen from Abstracts

Poster Session 1

TUESDAY, FEBRUARY 25

Metabolites Mediating Tissue Crosstalk

Christopher B. Newgard, Duke University Medical Center, USA
Hepatic Metabolic Regulatory Nodes Linked to Cardiometabolic Diseases

Claudio J. Villanueva, University of California, Los Angeles, USA
Adipose-Liver Crosstalk and Adaptive Thermogenesis

Anne C. Eichmann, Yale University School of Medicine, USA
Role of Lactals in Diet-Induced Obesity

Rebecca A. Haeusler, Columbia University, USA
Bile Acid Regulation of Metabolism

Short Talks Chosen from Abstracts

Workshop 1: Late-Breaking Research in Obesity and NAFLD

Short Talks Chosen from Abstracts

Drivers of NAFLD and Dyslipidemia in Obesity

Elizabeth J. Parks, University of Missouri, USA
Liver Metabolic Flux in NAFLD and NASH

Greg Steinberg, McMaster University, Canada
Cellular Energy Sensing: Implications for Treating NAFLD

Lale Ozcan, Columbia University, USA
Glucagon-Mediated Regulation of Lipid Metabolism

Short Talks Chosen from Abstracts

Poster Session 2

WEDNESDAY, FEBRUARY 26

Obesity Pathogenesis and New Protein Therapeutic Strategies

Nancy A. Thornberry, Kallyope, Inc., USA
Gut-to-Brain Axis of Communication

Lotte Bjerre Knudsen, Novo Nordisk A/S, Denmark
GLP-1R Agonists: Mechanisms Relevant for the Treatment of Obesity and NASH

Alexei Kharitonov, Novo Nordisk, USA
Novel FGF21 Variants

Hank Mansbach, 89bio, USA
BIO89-100, a Long-Acting FG21 Analog, for Treatment of NASH and Cardio-Metabolic Disorders

Short Talks Chosen from Abstracts

Pathogenesis of NASH and Liver Fibrosis

Bart Staels, Institut Pasteur de Lille, Université Lille, France
Pathways in the Transition of Fatty Liver to Active Disease NASH

Utpal B. Pajvani, Columbia University Medical Center, USA
Reactivation of Developmental Pathways in NASH

Anna Mae Diehl, Duke University, USA
Fixing Fatty Livers

Short Talks Chosen from Abstracts

Poster Session 3

THURSDAY, FEBRUARY 27

Adipose Tissue and Organismal Energy Balance

Shingo Kajimura, University of California, San Francisco, USA
The Roles of Brown Adipose Tissue Beyond Thermogenesis

Karine Clément, INSERM/Sorbonne Université, France
Origins of Adipose Tissue Fibrosis

Alexander S. Banks, Harvard Medical School, USA
Novel Signaling Pathways in Adipose Tissue

Silvia Corvera, University of Massachusetts Medical School, USA
Mechanisms Controlling Number and Type of Adipocytes

Short Talks Chosen from Abstracts

Workshop 2: Late-Breaking Drug Targets

Short Talks Chosen from Abstracts

Obesity & NAFLD: Bridging Basic Discoveries and Clinical Application

Robert K. Semple, University of Edinburgh, UK
Understanding Liver Metabolic Dysfunction Using Human Genetics

Jan Borén, University of Gothenburg, Sweden
Novel Interventions for NAFLD

Brian Finan, Novo Nordisk, USA
Peptide Triagonists for the Treatment of Obesity and Diabetes

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Obesity and NAFLD: Mechanisms and Therapeutics (B3)

February 23-27, 2020 • Fairmont Banff Springs • Banff, AB, Canada

Scientific Organizers: Rebecca A. Haeusler, Shingo Kajimura and Alexei Kharitonov

Sponsored by Gilead Sciences, Inc. and Novo Nordisk A/S

Discounted Abstract & Scholarship Deadline: October 23, 2019 / Abstract Deadline: November 21, 2019 / Discounted Registration Deadline: December 19, 2019

Short Talk Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, FEBRUARY 28

Departure